Publications
66
Citations
276
Est. group size
~4
Recurring co-author estimate
Active years
13
Publishing since 2014
Julia Selich-Anderson studies the molecular biology of pediatric cancers, particularly Ewing sarcoma and neuroblastoma. Her work focuses on cancer-driving fusion proteins like EWSR1::FLI1, how they bind DNA to control gene activity, and how experimental drugs (such as seclidemstat) might block their cancer-promoting effects. She also investigates biomarkers, such as PBX1, that help predict patient outcomes and treatment response in neuroblastoma.
Publication output was modest and variable from 2017-2022, spiked sharply in 2023 (likely due to a single multi-part dataset publication), and has since returned to a lower, steady pace through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Reviewer #1 (Public review): The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
2026
- The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
eLife · 2026
- Author response: The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
2026
- Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion–Positive Sarcomas
Cancer Research Communications · 2025
- Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- Data from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
2023
- bioRxiv (Cold Spring Harbor Laboratory)×6
- eLife×5
- Cancer Research×3
- Nucleic Acids Research×1
- Nature Cell Biology×1
- Stephen L. Lessnick
Medicine · The Ohio State University
- Lucia Casadei
Medicine · The Ohio State University
- Michael J. Ferguson
Medicine · Indiana University
- Pankita H. Pandya
Medicine · Indiana University
- Karen E. Pollok
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile